Literature DB >> 11287022

Serum human chorionic gonadotropin levels are correlated with body mass index rather than route of administration in women undergoing in vitro fertilization--embryo transfer using human menopausal gonadotropin and intracytoplasmic sperm injection.

K E Elkind-Hirsch1, S Bello, L Esparcia, K Phillips, A Sheiko, M McNichol.   

Abstract

OBJECTIVE: To compare subcutaneous (SC) and intramuscular (IM) hCG administration and their association with body mass index (BMI) in women undergoing IVF-ET using hMG and ICSI.
DESIGN: Prospective, randomized controlled trial.
SETTING: Private infertility clinic. PATIENT(S): Twenty-one ovulatory women, 29-39 years, were enrolled. Treatment of one patient who failed to respond to hMG was canceled. INTERVENTION(S): A standard IVF-ET treatment plan using an initial dose of 300 U of hMG was followed. Patients were randomly assigned to receive 10,000 IU hCG, either IM in the gluteal region or SC in the lower abdomen. Exactly 12 hours later, serum for hCG determination was obtained. All oocytes were fertilized using ICSI technology. MAIN OUTCOME MEASURE(S): Human chorionic gonadotropin levels 12 hours after injection, BMI, and oocyte maturity. RESULT(S): No significant differences in hCG levels were found, with mean levels of 225 +/- 24 mIU/mL for SC injection versus 213 +/- 26 mIU/mL for IM injection. No differences were observed in the percentage of mature oocytes. A significant negative correlation was found between BMI and hCG levels in all patients, regardless of route of administration. CONCLUSION(S): The highest levels of hCG were measured in women with the lowest BMI. Patients' body size, rather than route of hCG delivery, appears to determine circulating levels of hCG.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11287022     DOI: 10.1016/s0015-0282(00)01790-8

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  8 in total

Review 1.  Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.

Authors:  Ali Abbara; Sophie A Clarke; Waljit S Dhillo
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

2.  Human chorionic gonadotropin (hCG) plasma levels at oocyte retrieval and IVF outcomes.

Authors:  R Matorras; A Meabe; R Mendoza; B Prieto; O Ramón; J Mugica; F Aspichueta; A Exposito
Journal:  J Assist Reprod Genet       Date:  2012-07-20       Impact factor: 3.412

3.  Human chorionic gonadotropin serum levels following ovulation triggering and IVF cycle outcome.

Authors:  Yossi Mizrachi; Eran Horowitz; Jacob Farhi; David Levran; Arieh Raziel; Ariel Weissman
Journal:  J Assist Reprod Genet       Date:  2018-03-23       Impact factor: 3.412

4.  Serum human chorionic gonadotropin levels on the day before oocyte retrieval do not correlate with oocyte maturity.

Authors:  Gary Levy; Micah J Hill; Christina Ramirez; Torrie Plowden; Justin Pilgrim; Robin S Howard; James H Segars; John Csokmay
Journal:  Fertil Steril       Date:  2013-01-30       Impact factor: 7.329

5.  Pharmacokinetics of human chorionic gonadotropin injection in obese and normal-weight women.

Authors:  Divya K Shah; Stacey A Missmer; Katharine F B Correia; Elizabeth S Ginsburg
Journal:  J Clin Endocrinol Metab       Date:  2014-01-29       Impact factor: 5.958

6.  Low-Dose Urinary Human Chorionic Gonadotropin Is Effective for Oocyte Maturation in In Vitro Fertilization/ Intracytoplasmic Sperm Injection Cycles Independent of Body Mass Index.

Authors:  Luis R Hoyos; Sana Khan; Jing Dai; Manvinder Singh; Michael P Diamond; Elizabeth E Puscheck; Awoniyi O Awonuga
Journal:  Int J Fertil Steril       Date:  2016-11-11

7.  The effect of human chorionic gonadotrophin contained in human menopausal gonadotropin on the clinical outcomes during progestin-primed ovarian stimulation.

Authors:  Xiuxian Zhu; Jing Ye; Yonglun Fu; Ai Ai; Renfei Cai; Yun Wang; Qingging Hong; Tian Hui; Qifeng Lyu; Qiuju Chen; Yanping Kuang
Journal:  Oncotarget       Date:  2017-08-24

8.  First-in-human trial assessing the pharmacokinetic-pharmacodynamic profile of a novel recombinant human chorionic gonadotropin in healthy women and men of reproductive age.

Authors:  Lars-Erik Broksø Kyhl; Christiane Hesse; Per Larsson; Katharina Bruzelius; Bernadette Mannaerts
Journal:  Clin Transl Sci       Date:  2021-06-21       Impact factor: 4.689

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.